Strides Pharma Science Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for STAR, BSE:532531 Strides Pharma Science Ltd.

Strides Pharma Science Ltd.

07 Aug 2021

1001.15

0.12%

Lack of launches / COVID disruption leads to weak 1QFY22

Buy: Strides Pharma Science Ltd.

Target

Motilal Oswal

Strides Pharma (STR) reported unexpected operational loss in 1QFY22 on lower demand, higher competitive intensity in US Generics, and low operating leverage. This was exacerbated by the impact on production and supply due to a severe second COVID wave in Bengaluru. As a quick mitigation plan to increase product launches, it aims to acquire a portfolio of differentiated ANDAs, including 20 already commercialized products and a manufacturing facility from Endo Pharma in the US. The acquisition would double the approved product portfolio and add...

Strides Pharma Science Ltd. is trading above all available SMAs

Strides Pharma Science Ltd.

03 Jun 2021

1001.15

0.12%

STRIDES PHARMA SCIENCE LIMITED

Buy: Strides Pharma Science Ltd.

Recommendation Target

Geojit BNP Paribas

The emerging markets grew by 107% YoY with growth in institutional biz. driven by TDL. The company announced its partnership with TLC to launch Amphotericin B Liposome for Injection 50mg. We expect a revenue CAGR of 15% over FY21E-FY23E on the back of strong existing product portfolio, new product basket to aid COVID treatment and strengthening of front-end presence. Hence, we upgrade our rating from Accumulate to Buy based on...

Geojit BNP Paribas upgraded Strides Pharma Science Ltd. to Buy with a price target of 1119.0 on 27 Mar, 2026.

Strides Pharma Science Ltd.

28 May 2021

1001.15

0.12%

US/Institutional business drives earnings

Buy: Strides Pharma Science Ltd.

Target

Motilal Oswal

STR's 4QFY21 operational performance was marginally below our estimate. The robust performance in the US/Institutional segment within emerging markets was offset by subdued sales in other regulated markets on account of COVID-19. In addition to commercial manufacturing of the Sputnik vaccine by Oct'21, STR is building a basket of COVID-related medicines. The...

Strides Pharma Scien.. has an average target of 1119.00 from 1 broker.

Strides Pharma Science Ltd.

06 Feb 2021

1001.15

0.12%

STRIDES PHARMA SCIENCE LIMITED

Accumulate: Strides Pharma Science Ltd.

Target

Geojit BNP Paribas

The other regulated markets grew by 37% YoY with strong growth and market share increase in the UK, Europe and Australia. The company announced the approval to de-merge Stelis Biopharma into a standalone entity and publicly list the entity. We expect a revenue/PAT CAGR of 10%/28% over FY21E-FY23E on the...

Strides Pharma has gained 62.71% in the last 1 Year

Strides Pharma Science Ltd.

04 Feb 2021

1001.15

0.12%

Slower US/Africa biz drag down earnings

Buy: Strides Pharma Science Ltd.

Target

Motilal Oswal

Strides Pharma (STR)'s 3QFY21 performance came in below estimates due to the COVID-related impact on the US and Africa biz. Recovery in the Other Regulated (OTR) business was led by healthy volume traction. At the strategic level, STR would de-merge its Biotech business under Stelis Biopharma and intends to list this, thereby unlocking value for shareholders. We cut our earnings estimate by 19%/7%/5% for FY21/FY22/FY23, accounting for weak Flu season related demand in the US and slower offtake of medicines related to Acute therapies in the Africa business. We roll...

Strides Pharma has gained 62.71% in the last 1 Year

Strides Pharma Science Ltd.

30 Oct 2020

1001.15

0.12%

2Q - COVID-led aberration hurts performance

Buy: Strides Pharma Science Ltd.

Target

Motilal Oswal

Strides Pharma (STR)'s 2QFY21 performance came in below estimates due to COVID-related a) disruptions at its manufacturing facilities and b) softness in demand in the UK / select European countries. However, the outlook remains positive, with normalcy back in manufacturing operations. We cut our earnings estimate by 10.2%/4.9% for FY21/FY22, factoring in COVID-related disruption in 2QFY21. We value STR on a 12M forward SOTP basis EV/EBITDA of 11x for Regulated segment, 6x for Emerging Markets (EM) segment, and 7x for Institutional segment to arrive at Target Price of...

Promoters unpledged 13.53% of shares in last quarter. Total pledge stands at 30.60% of promoter holdings

Strides Pharma Science Ltd.

29 Oct 2020

1001.15

0.12%

Strides Pharma

Buy: Strides Pharma Science Ltd.

Sharekhan

Q2FY2021 was a soft quarter for Strides. The results missed estimates. Revenues grew 11% YoY to Rs 793 crore while the adjusted PAT at Rs 44 crore declined by 9%. Strtides expects a marked improvement in its performance in 2HFY2021 as compared...

Geojit BNP Paribas upgraded Strides Pharma Science Ltd. to Buy with a price target of 1119.0 on 27 Mar, 2026.

Strides Pharma Science Ltd.

06 Aug 2020

1001.15

0.12%

Strong revival in earnings led by Other Regulated / Africa

Buy: Strides Pharma Science Ltd.

Target

Motilal Oswal

We roll our price target to INR650 on a 12M forward SOTP basis (8x EV/EBITDA for the US / Other Regulated markets, 6x for Emerging Markets, and 5x for Institutional). Considering this and its increased market share in commercialized products, we expect US sales to revive and exhibit a 6% CAGR to USD270m over STR recorded the highest ever quarterly revenue of INR2.6b in the Other Regulated market, implying growth of 53% on a YoY basis in 1QFY21. We expect the business to exhibit a 23% CAGR in sales to INR12.6b over STR exhibited 17% YoY / 47% QoQ growth in the Emerging Markets business, led by an increase in primary sales in Africa. in Other Regulated and 52% sales CAGR in Emerging Markets, supported by our price target to INR650 on a 12M forward SOTP basis (8x EV/EBITDA for US / Other Regulated, 6x for Emerging Markets, and 5x for Institutional).

Promoters unpledged 13.53% of shares in last quarter. Total pledge stands at 30.60% of promoter holdings

Strides Pharma Science Ltd.

26 May 2020

1001.15

0.12%

STRIDES PHARMA SCIENCE LIMITED

Accumulate: Strides Pharma Science Ltd.

Target

Geojit BNP Paribas

We upgrade our rating to Accumulate based on 10x FY22 EPS with a target of price of Rs.485 as new launches in U.S and other regulated markets will drive growth. Revenues were down 26% yoy and down 16% qoq mainly on...

Number of FII/FPI investors increased from 275 to 289 in Dec 2025 qtr.

Strides Pharma Science Ltd.

17 Mar 2020

1001.15

0.12%

STRIDES PHARMA SCIENCE LIMITED

Hold: Strides Pharma Science Ltd.

Recommendation Target

Geojit BNP Paribas

The U.S sales grew 62% YoY (16% QoQ) during the quarter, with the move to front end sales paying dividends. Other regulated markets saw 54% in YoY growth in revenue, led by...

Number of FII/FPI investors increased from 275 to 289 in Dec 2025 qtr.

Is Strides Pharma Science Ltd. worth buying?

494 Votes:

Buy 78.95%

Sell 11.74%

Hold 9.31%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Accumulate SEE REPORTS >

pdf